TENX Company Profile and Key Details

Q: Who are the executives of TENX?

Mr. Doug RandallExecutive Vice President of Commercial & Bus. OperationsMs. Nancy J. M. HecoxExecutive Vice President of Legal Affairs, Gen. Counsel & Corporation Sec.Dr. Douglas HaySenior Vice President of Regulatory AffairsMr. Christopher T. GiordanoChief Executive Officer, Pres & DirectorDr. Stuart Rich M.D.Chairman of Scientific Advisory Board, Chief Medical Officer & Director

NASDAQ : TENX

Tenax Therapeutics

$12.25

0.25+2.08%

At Close 4:00 PM

69.65

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Tenax Therapeutics, Inc. (TENX) stock surged +2.08%, trading at $12.25 on NASDAQ, up from the previous close of $12.00. The stock opened at $12.50, fluctuating between $11.86 and $12.70 in the recent session.

Stock Snapshot

Prev. Close

210.67M

Market Cap

11.861

Day Low

-8.69

P/E Ratio

-1.41

EPS (TTM)

-19.79

Cash Flow per Share

12.5

Open

17.2M

Number of Shares

12.7

Day High

98.76%

Free Float in %

27.15

Book Value

869.02K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 22, 2026	12.50	12.70	11.86	12.25	877.06K
Jun 18, 2026	11.94	12.28	11.78	12.00	2.69M
Jun 17, 2026	11.26	11.97	11.26	11.87	1.28M
Jun 16, 2026	11.50	11.57	11.20	11.33	789.89K
Jun 15, 2026	11.65	11.74	11.11	11.55	759.93K
Jun 12, 2026	11.36	12.30	11.27	11.48	1.77M
Jun 11, 2026	10.51	11.00	10.30	10.73	929.38K
Jun 10, 2026	10.63	11.00	10.53	10.55	381.12K
Jun 09, 2026	10.55	10.99	10.25	10.73	1.45M
Jun 08, 2026	10.89	11.15	10.54	10.54	587.91K
Jun 05, 2026	11.07	11.07	10.57	10.73	560.37K
Jun 04, 2026	10.75	11.57	10.75	11.09	882.55K
Jun 03, 2026	10.90	11.34	10.76	10.77	551.23K
Jun 01, 2026	11.80	12.10	11.50	11.97	1.66M
May 29, 2026	11.67	11.95	11.42	11.87	390.37K
May 28, 2026	11.88	11.96	11.56	11.69	624.09K
May 27, 2026	11.98	12.44	11.81	11.88	497.6K
May 26, 2026	12.35	12.45	11.95	11.98	351.88K
May 22, 2026	12.36	12.44	11.94	12.13	219.57K
May 21, 2026	11.89	12.75	11.85	12.36	443.2K

Contact Details

Chapel Hill, NC 27560

United States

https://www.tenaxthera.com 919 855 2100

About Company

Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.

Stock Peers

ARGX

26.03+2.97%

argenx SE$903.75 REGN

2.56+0.42%

Regeneron Pharmaceuticals, Inc.$612.50 UTHR

1.70998+0.32%

United Therapeutics Corporation$538.30 MDGL

7.13+1.41%

Madrigal Pharmaceuticals, Inc.$512.88 VRTX

15.16+3.36%

Vertex Pharmaceuticals Incorporated$466.79 KRYS

-4.63-1.33%

Krystal Biotech, Inc.$343.43 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

21.08+7.47%

Praxis Precision Medicines, Inc.$303.39 ALNY

8.32+2.99%

Alnylam Pharmaceuticals, Inc.$286.41 LGND

-12.71-4.62%

Ligand Pharmaceuticals Incorporated$262.17

Company Overview

Tenax Therapeutics, Inc. (NASDAQ:TENX) closed at $12.25 USD, gaining $0.25 (2.08%) from the previous close of $12.00. The stock is currently mid-range between its 52-week high and low $5.62 and $18.38. With a market capitalization of about $210.67 million, Tenax Therapeutics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.97). Key stats such as the average daily volume over the past year has been around 690.30 thousand shares, in line with its 52-week average. Headquartered in Chapel Hill, NC, Tenax Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Christopher T. Giordano, the company employs approximately 4 people and listed since April 04, 1994. Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada.

Technical Performance

TENX has shown sold momentum, gaining 11.7% over the past week and 145.62% over the past quarter, though year-to-date performance is up 34.7%. Short-term trend indicators are mixed aligned (SMA20 -6.71%, SMA50 -10.68%, SMA200 41.57%). The stock’s 14-day RSI is 40.88 (neutral), while the ATR of 0.95 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -36.07% below its high and over 153.78% above its low. Average 10-day trading volume of 1.28 million shares is significantly above the 3-month average of 685.93 thousand, indicating heightened recent market interest.

Valuation Metrics

Tenax Therapeutics, Inc. trades at a P/E ratio of -8.5, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.72 trading at moderately above to book value. The P/FCF stands at -5.4, also above market averages.

Dividend & Fair Value

Tenax Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.49. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Tenax Therapeutics, Inc. generated EPS of -$1.13 over the past year. Five-year average earnings growth is 77.86%. Wall Street analysts project EPS growth of -27.39% annually over the next five years. The latest quarter delivered EPS of -$0.35. The next quarter is forecast at -$0.41. Next year's EPS is expected at $1.43. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $50.00 to $14.00. The high target offers 308.16% upside. The low target suggests 14.29% downside. The mean target is $30.62. This offers 149.96% upside. Tenax Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 12, 2026, missed forecasts by -12.5%. The prior quarter beat by -69.84%. Over the last six quarters, Apple has recorded several small beats. These include -65.38% in March 25, 2025.

Shareholding & Insider Activity

Tenax Therapeutics, Inc. has 4.56 million shares outstanding. The public float is 4.51 million shares, elevated short interest at 7.38% of float. This equals 326.90 thousand shares. The short ratio is 14.14 days. Institutional investors hold 76.35% of the float. Insiders own 0.12%. ARMISTICE CAPITAL, LLC holds 2.02 million shares, Kiral Richard M has 105.00 thousand shares and Mitchum James P. has 19.00 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Tenax Therapeutics has not generated any revenue. Returns are negative, with ROA at -65.99% and ROE at -95.22%.
On valuation metrics, Tenax Therapeutics trades at a P/E of -8.50, P/S of 0.00 and P/B of 4.72. The current ratio is 14.52 and quick ratio is 14.52.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Tenax Therapeutics posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $7.57K (margin 0.00%). Operating income was - $8.23M (margin 0.0%). Net income was- $7.71M (EPS - $31.04).
The company ended the quarter with $9.79M in cash and short-term investments, a total debt of $500.90K, and net debt of - $9.29M. Total assets were $11.68M, with equity of $8.10M. Financials further reflected weakness, with operating cash flow of - $5.90M, free cash flow of - $5.90M, and capital expenditures of $2.84K.

Price Forecast & Outlook

Our AI price prediction model suggests that Tenax Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.35%, with price expected at $11.84 by July 06, 2026, within a range of $11.21 to $12.48 3-Month Outlook: Projected fall of -10.2%, reaching $11.00 by September 16, 2026, with a range of $10.76 to $11.22. 1-Year Outlook: Projected gain of 170.53%, with price at $33.14 by June 22, 2027, within a range of $22.57 to $42.65.

Key Takeaways

Tenax Therapeutics, Inc. (NASDAQ:TENX) shares are up 34.7% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Tenax Therapeutics, Inc. trading at a premium to the broader market with a P/E of -8.5. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $23.83, suggesting 94.53% upside. Our AI forecast model points to short-term weakness (-3.35% over two weeks), a medium-term fall (-10.2% over three months), and a longer-term gain (170.53% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Tenax Therapeutics, Inc. (TENX) stock price?

Tenax Therapeutics, Inc. (NASDAQ: TENX) stock price is $12.25 in the last trading session. During the trading session, TENX stock reached the peak price of $12.70 while $11.86 was the lowest point it dropped to. The percentage change in TENX stock occurred in the recent session was 2.08% while the dollar amount for the price change in TENX stock was $0.25.

TENX's industry and sector of operation?

The NASDAQ listed TENX is part of Biotechnology industry that operates in the broader Healthcare sector. Tenax Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of TENX?

Mr. Doug Randall
Executive Vice President of Commercial & Bus. Operations
Ms. Nancy J. M. Hecox
Executive Vice President of Legal Affairs, Gen. Counsel & Corporation Sec.
Dr. Douglas Hay
Senior Vice President of Regulatory Affairs
Mr. Christopher T. Giordano
Chief Executive Officer, Pres & Director
Dr. Stuart Rich M.D.
Chairman of Scientific Advisory Board, Chief Medical Officer & Director

How TENX did perform over past 52-week?

TENX's closing price is 118.13% higher than its 52-week low of $5.62 where as its distance from 52-week high of $18.38 is -33.35%.

How many employees does TENX have?

Number of TENX employees currently stands at 4.

Link for TENX official website?

Official Website of TENX is: https://www.tenaxthera.com

How do I contact TENX?

TENX could be contacted at phone 919 855 2100 and can also be accessed through its website. TENX operates from ONE Copley Parkway, Chapel Hill, NC 27560, United States.

How many shares of TENX are traded daily?

TENX stock volume for the day was 869.02K shares. The average number of TENX shares traded daily for last 3 months was 690.3K.

What is the market cap of TENX currently?

The market value of TENX currently stands at $210.67M with its latest stock price at $12.25 and 17.2M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	4
Beta	0.97
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

TENX Company Profile and Key Details

Tenax Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways